Tuesday, November 28, 2023
GE Healthcare has launched the MyBreastAI Suite, an innovative all-in-one platform featuring artificial intelligence (AI) applications designed to assist clinicians in breast cancer detection and streamline workflow productivity. In its initial release, the MyBreastAI Suite seamlessly integrates three AI applications from iCAD: ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment. These applications aim to enhance early detection, improve patient outcomes, and optimize operational efficiency in radiology departments.
Facing challenges such as burnout, workforce attrition, and patient backlogs amidst the global rise in cancer cases, radiologists are in need of solutions. The MyBreastAI Suite addresses these challenges by providing a unified platform that smoothly integrates AI into the breast imaging workflow. The three integrated AI applications from iCAD's ProFound Breast Health Suite offer unique capabilities:
ProFound AI for DBT: This application, trained with an extensive 3D image dataset, delivers critical information to radiologists, including lesion Certainty of Finding and Case Scores. These insights help prioritize caseloads, support clinical decision-making, and potentially reduce burnout.
SecondLook for 2D Mammography: A Computer-Aided Detection (CAD) system, it identifies and marks regions of interest on screening and diagnostic mammograms from GE Healthcare's full-field digital mammography systems, aiding radiologists in reevaluating mammograms after an initial reading.
PowerLook Density Assessment: Standardizing breast density assessment and reducing variability among radiologists, this tool simplifies and standardizes reporting and stratification for clinicians. It provides accurate and reliable breast density assessments based on AI mammogram analysis.
Research indicates the positive impact of these digital solutions, demonstrating increased reader sensitivity by 8%, enhanced reader specificity by 6.9%, and a reduction in reading time by up to 52% compared to traditional methods. The MyBreastAI Suite represents a significant step forward in addressing challenges related to access, burnout, variability, equity, and cost in breast imaging, ultimately elevating the detection and diagnosis of breast cancer.
Source: businesswire.com
